Selskabsmeddelse nr. 3 / Årsrapport 2022
Selskabsmeddelelsenr. 3/2023
Erria A/S-KoncernenAnnoncerer Årsrapport for 2022
Indeholder intern viden
Årsrapport for 2022
Bestyrelsen i Erria A/S (”Erria”) har i dag godkendt årsrapporten for 2022 for koncernens aktiviteter. Omsætningen i perioden udgjorde DKK 157,9 mio. (2021: DKK 59,1 mio.) og driftresultat (EBIDTA) DKK 13,2 mio. (2021: DKK 1,8 mio.). Bestyrelsen betegner resultaterne som meget tilfredsstillende.
2022 var et usædvanligt stærkt år for Erria. Det bedste resultat i årevis var drevet af solide resultater på tværs af alle 4 selskaber (Erria A/S, Erria Container Services, Mermaid Maritime Vietnam & Cathay Seal).
Højdepunkter for 2022 for Erria A/S-Koncernen
- Omsætning DKK 157,9 mio. (2021: DKK 59,1 mio.)
- EBITDA DKK 13,2 mio. (2021: DKK 1,8 mio.)
- Årets resultat DKK 9,3 (2021: DKK 1,0 mio.)
- Bogført egenkapital DKK 3,9 mio. (2021: DKK minus 11,7 mio.)
Forventninger til 2023
- Omsætning 2023 DKK 170-185 mio. (2022: DKK 155-160 mio.)
- EBITDA 2023 DKK 5-8 mio. (2022: DKK 12,5-13,5 mio.)
- EBIT 2023 DKK 4-7 mio. (2022: Ikke oplyst – ny i 2023)
Erria forventer i 2023 lavere momentum i containerforretningen ECS. Men på trods af at afmatningen i den globale økonomi vil føre til lavere vækst i containerforretningen i 2023, vil Erria fortsætte med at forfølge vækstmulighederne i Asien inden for terminalforretning for at
stå endnu stærkere når markedet forventeligt normaliseres i 2024.
Med opkøbene af Mermaid & Cathay Seal som er fuldt integreret og med en Ørsted-aftale, der påvirker driften i hele 2023, forventer Erria endnu et stærkt år i 2023.
Væsentlige begivenheder siden 31. december 2021
Der er ikke indtruffet begivenheder, der væsentligt påvirker vurderingen af årsrapporten.
Erria afholder i samarbejde med HC Andersen Capital et virtuelt live event i morgen torsdag d. 9. marts kl. 09:00, hvor CEO Henrik N. Andersen vil præsentere Erria, highlights fra årsrapporten for 2022 og forventningerne til 2023 samt svare på spørgsmål.
Tilmelding er via dette link: https://www.inderes.dk/videos/erria-introduktion-til-aktien
Yderligere information
For yderligere information, kontakt venligst adm. direktør Henrik N. Andersen på +45 3336 4400.
Henrik N. Andersen
Adm. direktør
Søren Storgaard
Bestyrelsesformand
ERRIA (Nasdaq First North Growth Market Denmark): Ticker: ERRIA er forpligtet til at offentliggøre den ovenstående information i henhold til EU Markedsmisbrugsforordning punkt 17.
Certified adviser
Norden CEF A/S
John Norden
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release
Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern
ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release
SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release
If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and
Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342